Publications
2024
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using LC-MS/MS
2023
Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial
Herrera, C., Serwanga, J., Else, L., Limakatso, L., Opoka, D., Ssemata, A. S., . . . CHAPS. (2023). Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial. EBIOMEDICINE, 93. doi:10.1016/j.ebiom.2023.104648
Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS
Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057
Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.
Maddox, V., Reynolds, C., Amara, A., Else, L., Brailsford, S. R., Khoo, S., & Harvala, H. (2023). Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 28(11). doi:10.2807/1560-7917.es.2023.28.11.2300135
2022
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463
Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019
Harvala, H., Reynolds, C., Ijaz, S., Maddox, V., Penchala, S. D., Amara, A., . . . Khoo, S. (2022). Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. SEXUALLY TRANSMITTED INFECTIONS, 98(2), 132-135. doi:10.1136/sextrans-2021-054981
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2
2021
The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva
Amara, A., Penchala, S. D., Else, L., Hale, C., FitzGerald, R., Walker, L., . . . Khoo, S. (2021). The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206. doi:10.1016/j.jpba.2021.114356
Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (n.d.). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 6, 246. doi:10.12688/wellcomeopenres.17202.1
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
Dickinson, L., Walimbwa, S., Singh, Y., Kaboggoza, J., Kintu, K., Sihlangu, M., . . . Orrell, C. (2021). Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. CLINICAL INFECTIOUS DISEASES, 73(5), E1200-E1207. doi:10.1093/cid/ciaa1861
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)
Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136
2020
Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial
Nash, S., Dietrich, J., Ssemata, A. S., Herrera, C., O'Hagan, K., Else, L., . . . Fox, J. (2020). Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-020-04760-x
2019
Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman.
Feiterna-Sperling, C., Krüger, R., Amara, A., Khoo, S., & Waitt, C. (2019). Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman.. AIDS (London, England), 33(15), 2443-2444. doi:10.1097/qad.0000000000002360
Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman
Feiterna-Sperling, C., Krueger, R., Amara, A., Khoo, S., & Waitt, C. (2019). Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman. AIDS, 33(15), 2443-2444. doi:10.1097/QAD.0000000000002360
Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine"
Walimbwa, S., Lamorde, M., Waitt, C., Amara, A., & Khoo, S. (2019). Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(6). doi:10.1128/AAC.00593-19
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019)
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
Walimbwa, S. I., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. H. (2019). Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(2). doi:10.1128/AAC.01310-18
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)
Waitt, C., Orrell, C., Walimbwa, S., Singh, Y., Kintu, K., Simmons, B., . . . Khoo, S. (2019). Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLOS MEDICINE, 16(9). doi:10.1371/journal.pmed.1002895
2018
Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk
Gini, J., Penchala, S. D., Amara, A., Challenger, E., Egan, D., Waitt, C., . . . Else, L. J. (2018). Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. BIOANALYSIS, 10(23), 1933-1945. doi:10.4155/bio-2018-0085
Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.
Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749
Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)
Imaz, A., Niubo, J., Amara, A., Khoo, S., Ferrer, E., Tiraboschi, J. M., . . . Podzamczer, D. (2018). Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). JOURNAL OF NEUROVIROLOGY, 24(4), 391-397. doi:10.1007/s13365-018-0626-4
Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
Walimbwa, S., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. (2018). Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. doi:10.1101/351684
2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. Retrieved from http://gateway.webofknowledge.com/
Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS
Waitt, C., Penchala, S. D., Olagunju, A., Amara, A., Else, L., Lamorde, M., & Khoo, S. (2017). Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. Journal of Chromatography B, 1060, 300-307. doi:10.1016/j.jchromb.2017.06.012
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2035-2041. doi:10.1093/jac/dkx108
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017)
Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2143. doi:10.1093/jac/dkx145
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study.
Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. doi:10.1097/FTD.0000000000000448
2016
The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma
Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake
Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease
Molto, J., Graterol, F., Miranda, C., Khoo, S., Bancu, I., Amara, A., . . . Clotet, B. (2016). Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2564-2566. doi:10.1128/AAC.03131-15
A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection.
Wang, X., Penchala, S. D., Amara, A., Else, L., McClure, M., & Boffito, M. (2016). A Validated Method for Quantification of Dolutegravir Using Ultra Performance Liquid Chromatography Coupled With UV Detection. THERAPEUTIC DRUG MONITORING, 38(3), 327-331. doi:10.1097/FTD.0000000000000286
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. (2016). Journal of the International AIDS Society, 19(8(Suppl 7)), 21487. doi:10.7448/ias.19.8.21487
2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation
Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots
Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174
Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317
A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry
Amara, A. B., Else, L. J., Tjia, J., Olagunju, A., Puls, R. L., Khoo, S., & Back, D. J. (2015). A Validated Method for Quantification of Efavirenz in Dried Blood Spots Using High-Performance Liquid Chromatography-Mass Spectrometry. THERAPEUTIC DRUG MONITORING, 37(2), 220-228. doi:10.1097/FTD.0000000000000127
Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
Winston, A., Amin, J., Clarke, A., Else, L., Amara, A., Owen, A., . . . Puls, R. (2015). Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial. CLINICAL INFECTIOUS DISEASES, 60(7), 1026-1032. doi:10.1093/cid/ciu976
Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics
Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420
Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.
Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.. The Journal of antimicrobial chemotherapy, 70(2), 555-561.
2014
<i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2014). <i>CYP2B6</i> 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients. THERAPEUTIC DRUG MONITORING, 36(6), 734-738. doi:10.1097/FTD.0000000000000098
Effects of Chronic Albumin Overload in Renal Proximal Tubular Cell Catabolism and on Oxidative Stress
Amara, A. B., Shalamanova, L., McArdle, F., Sharma, A., Jackson, M. J., & Rustom, R. (2014). Effects of Chronic Albumin Overload in Renal Proximal Tubular Cell Catabolism and on Oxidative Stress. TRANSPLANTATION.
2013
Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention
Jackson, A., Moyle, G., Watson, V., Tjia, J., Ammara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(3), 275-281. doi:10.1097/QAI.0b013e3182829bd0
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention
Jackson, A., Moyle, G., Watson, V., Tjia, J., Amara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62(3), 275-281. doi:10.1097/QAI.0b013e3182829bd0
A Validated Method for quantification of Efavirenz In Dried Blood Spots (DBS) using HPLC-MS/MS
Amara, A. B., Tjia, J., Else, L. J., Back, D. J., & Khoo, S. (2013). A Validated Method for quantification of Efavirenz In Dried Blood Spots (DBS) using HPLC-MS/MS.
CYP2B6rs3745274 and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients
Olagunju, A., Siccardi, M., Amara, A., Jevtovic, D., Kusic, J., Owen, A., & Dragovic, G. (2013). CYP2B6rs3745274 and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. Therapeutic Drug Monitoring.
Exposure of Breastfed Infants to Maternal Efavirenz from Breast Milk
Olagunju, A., Amara, A., Tjia, J., Siccardi, M., Oyigboja, J., Bolaji, O., . . . Owen, A. (2013). Exposure of Breastfed Infants to Maternal Efavirenz from Breast Milk. 20th Conference on Retroviruses and Opportunistic Infections (CROI), Atlant, 3-7.
2012
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.. AIDS research and treatment, 2012, 105980. doi:10.1155/2012/105980
Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
Development and validation of a HPLC-MS/MS assay to quantify the non-nucleoside reverse transcriptase inhibitor (NNRTI) anti-retroviral drug efavirenz in dried blood spots (abstract)
Amara, A. B., Tjia, J., Dutton, J., Else, L. J., Back, D. J., & Khoo, S. (2012). Development and validation of a HPLC-MS/MS assay to quantify the non-nucleoside reverse transcriptase inhibitor (NNRTI) anti-retroviral drug efavirenz in dried blood spots (abstract). BMSS Annual Meeting 2012 - SPEEDING THINGS UP, 33, 1.
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012, 1-6. doi:10.1155/2012/105980
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
2011
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. Antimicrobial Agents and Chemotherapy, 55(9), 4218-4223. doi:10.1128/aac.01747-10
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4218-4223. doi:10.1128/AAC.01747-10
Development and validation of a HPLC-MS/MS assay to quantify the anti-retroviral (ARV) drug, efavirenz and its major metabolites in plasma
Amara, A. B., Tjia, J., Dutton, J., Else, L. J., Back, D. J., & Khoo, S. (2011). Development and validation of a HPLC-MS/MS assay to quantify the anti-retroviral (ARV) drug, efavirenz and its major metabolites in plasma. Fast Atom Bombardment 32nd BMSS Meeting, Cardiff, 32, 1.
Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation
Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. . Antimicrob Agents Chemother., 55(9), 4218-4223.
Pharmacokinetics of lamivudine, and lamivudine-triphosphate after administration of 300 mg and 150 mg once-daily to healthy volunteers. The ENCORE 2 Study.
Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2011). Pharmacokinetics of lamivudine, and lamivudine-triphosphate after administration of 300 mg and 150 mg once-daily to healthy volunteers. The ENCORE 2 Study.. Antimicrobial Agents and Chemotherapy.
2010
Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy
Amara, A. B., Sharma, A., Alexander, J. L., Alfirevic, A., Mohiuddin, A., Pirmohamed, M., . . . Rustom, R. (2010). Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy. TRANSPLANTATION, 89(1), 104-114. doi:10.1097/TP.0b013e3181bf13d9
A Randomized Controlled Trial: Lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy
Amara, A. B., Sharma, A., Alexander, J. L., Alfirevic, A., Mohiuddin, A., Pirmohamed, M., . . . Rustom, R. (2010). A Randomized Controlled Trial: Lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Transplantation, 89(1), 104-114.
2007
Urinary Monocyte Chemoattractant Protein-1 (MCP-1) in Renal Transplant Recipients: Implications in Proteinuric Patients
Rustom, R., Amara, A. B., Shalamanova, L., Sharma, A., Shenkin, A., Bakran, A., . . . Hammad, A. (2007). Urinary Monocyte Chemoattractant Protein-1 (MCP-1) in Renal Transplant Recipients: Implications in Proteinuric Patients. The Open Transplantation Journal, 1(1), 1-6. doi:10.2174/1874418400701010001
Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor
Shalamanova, L., McArdle, F., Amara, A. B., Jackson, M. J., & Rustom, R. (2007). Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor. American Journal of Physiology-Renal Physiology, 292(6), F1846-F1857. doi:10.1152/ajprenal.00265.2006
Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor
Shalamanova, L., McArdle, F., Amara, A. B., Jackson, M. J., & Rustom, R. (2007). Albumin overload induces adaptive responses in human proximal tubular cells through oxidative stress but not via angiotensin II type 1 receptor. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 292(6), F1846-F1857. doi:10.1152/ajprenal.00265.2006
2005
Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy
Bone, J. M., Amara, A. B., Shenkin, A., Hammad, A., Seffis, R. A., Alexander, J. L., . . . Rustom, R. (2005). Calcineurin inhibitors and proximal renal tubular injury in renal transplant patients with proteinuria and chronic allograft nephropathy. TRANSPLANTATION, 79(1), 119-122. doi:10.1097/01.TP.0000146843.23824.93
Calcineurin Inhibitors and Proximal Renal Tubular Injury in Renal Transplant Patients with Proteinuria and Chronic Allograft Nephropathy
Bone, J. M., Amara, A. B., Shenkin, A., Sells, R. A., Hammad, A., Alexander, J., & Rustom, R. (2005). Calcineurin Inhibitors and Proximal Renal Tubular Injury in Renal Transplant Patients with Proteinuria and Chronic Allograft Nephropathy. Transplantation, 79(5).
2001
Renal tubular peptide catabolism in chronic vascular rejection
Rustom, R., Grime, J. S., Sells, R. A., Amara, A., Jackson, M. J., Shenkin, A., . . . Bone, J. M. (2001). Renal tubular peptide catabolism in chronic vascular rejection. RENAL FAILURE, 23(3-4), 517-531. doi:10.1081/JDI-100104734
Long-term evaluation of electrospray ionization mass spectrometric analysis of glycated hemoglobin
Roberts, N. B., Amara, A. B., Morris, M., & Green, B. N. (2001). Long-term evaluation of electrospray ionization mass spectrometric analysis of glycated hemoglobin. CLINICAL CHEMISTRY, 47(2), 316-321. Retrieved from https://www.webofscience.com/